Q8R4W6
Gene name |
Pcolce2 (Pcpe2) |
Protein name |
Procollagen C-endopeptidase enhancer 2 |
Names |
Procollagen COOH-terminal proteinase enhancer 2, PCPE-2, Procollagen C-proteinase enhancer 2 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:76477 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q8R4W6
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q8R4W6-F1 | Predicted | AlphaFoldDB |
23 variants for Q8R4W6
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs248623520 | 4 | A>T | No | EVA | |
| rs259336839 | 18 | R>Q | No | EVA | |
| rs225579834 | 115 | V>I | No | EVA | |
| rs3389038895 | 156 | R>C | No | EVA | |
| rs246293854 | 163 | T>S | No | EVA | |
| rs3389031242 | 169 | W>G | No | EVA | |
| rs3400327013 | 171 | D>H | No | EVA | |
| rs3389067180 | 173 | D>E | No | EVA | |
| rs3400617177 | 174 | Y>* | No | EVA | |
| rs244917697 | 189 | N>S | No | EVA | |
| rs3389042982 | 214 | V>L | No | EVA | |
| rs3389031303 | 216 | N>K | No | EVA | |
| rs387095579 | 219 | E>K | No | EVA | |
| rs3389072798 | 225 | R>S | No | EVA | |
| rs3389067194 | 229 | Y>F | No | EVA | |
| rs3389052314 | 255 | L>* | No | EVA | |
| rs3389059659 | 261 | I>F | No | EVA | |
| rs3389031304 | 263 | H>L | No | EVA | |
| rs3389057684 | 270 | K>R | No | EVA | |
| rs215064913 | 276 | T>A | No | EVA | |
| rs36826250 | 303 | M>T | No | EVA | |
| rs3389065836 | 309 | N>I | No | EVA | |
| rs3399995282 | 380 | Q>H | No | EVA |
No associated diseases with Q8R4W6
5 regional properties for Q8R4W6
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | CUB domain | 32 - 143 | IPR000859-1 |
| domain | CUB domain | 153 - 267 | IPR000859-2 |
| domain | Netrin domain | 296 - 414 | IPR001134 |
| domain | Netrin module, non-TIMP type | 307 - 412 | IPR018933 |
| domain | Procollagen C-endopeptidase enhancer, NTR domain | 291 - 414 | IPR035814 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| collagen-containing extracellular matrix | An extracellular matrix consisting mainly of proteins (especially collagen) and glycosaminoglycans (mostly as proteoglycans) that provides not only essential physical scaffolding for the cellular constituents but can also initiate crucial biochemical and biomechanical cues required for tissue morphogenesis, differentiation and homeostasis. The components are secreted by cells in the vicinity and form a sheet underlying or overlying cells such as endothelial and epithelial cells. |
| extracellular region | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| collagen binding | Binding to collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%). |
| heparin binding | Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. |
| peptidase activator activity | Binds to and increases the activity of a peptidase, any enzyme that catalyzes the hydrolysis peptide bonds. |
1 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to leukemia inhibitory factor | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukemia inhibitory factor stimulus. |
3 homologous proteins in AiPD
| 10 | 20 | 30 | 40 | 50 | 60 |
| MGGASACIPL | CLLLATARMA | RPQTPERPVF | TCGGILTGES | GFIGSEGFPG | MYPPNSKCTW |
| 70 | 80 | 90 | 100 | 110 | 120 |
| KITVPEGKVV | VLNFRFIDLE | NDNLCRYDFV | DVYNGHANGQ | RIGRFCGTFR | PGSLVASGNK |
| 130 | 140 | 150 | 160 | 170 | 180 |
| MTVQMISDAN | TAGSGFMATY | SAAAPDGKGD | RYCGGRLEKP | SGTFKTPNWP | DRDYPVGVTC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| VWHIIAPKNQ | LIELKFEKFD | VERDNYCRYD | YVAVFNGGEV | NDAKRIGKYC | GDSPPVPIVS |
| 250 | 260 | 270 | 280 | 290 | 300 |
| ERNELLIQFL | SDLSLTADGF | IGHYKFRPKK | FPTTTTTPVT | TTLPVTTGLK | PTVALCQQKC |
| 310 | 320 | 330 | 340 | 350 | 360 |
| RRMGTLESNY | CSSNFVLAGT | VITTVTRGGS | LHATVSIISI | YREGNLAIQQ | AGKNMSVKLT |
| 370 | 380 | 390 | 400 | 410 | |
| VVCRQCPLLR | RGLNYIIMGQ | VGEDGRGKIM | PNSFVKMFKN | KNQKPMNALK | NKQC |